glp-1 microdosing research Explained: A New Approach to Weight Management and Wellness Microdosing GLP-1 for Fat Loss

In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study (64) despite comparable putative GLP-1R occupancy at these doses (47)

These peptides act on the growth hormone axis, which is separate from testosterone

When taking oral semaglutide , it is strictly advised not to breastfeed

The weight does not keep accumulating, but without active management it often stays, because the underlying hormonal environment that made it easier to maintain weight has changed permanently